Andecaliximab
Andecaliximab Basic information
- Product Name:
- Andecaliximab
- Synonyms:
-
- Andecaliximab
- Research Grade Andecaliximab(DHD06801)
- GS-5745
- Research Grade Andecaliximab
- CAS:
- 1518996-49-0
- MW:
- 0
- Mol File:
- Mol File
Andecaliximab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Andecaliximab Usage And Synthesis
Uses
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF)[1][2].
in vivo
Andecaliximab improves T-cell receptor (TCR) diversity (decreased clonality) within tumor-infiltrating T-cell[1]. Andecaliximab (20 mg/kg; i.p. once) shows the antifibrotic efficacy in a humanized NSG mouse model of idiopathic pulmonary fibrosis[2].
| Animal Model: | Humanized nonobese diabetic, SCID, IL-2 receptor g (NSG) mouse model of IPF[2] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection; 20 mg/kg, once a week for once |
| Result: | Decreased SMAD2 phosphorylation and increased surfactant protein C. Reduced MMP9+ cells, including MMP9+, CCR10+ and MMP9+CD45- and EpCAM+CCR10+ subpopulations. |
References
[1] Andrew E. Greenstein, et al. Effect of andecaliximab (anti-MMP9) on proteolysis of IL-7 in vitro, TCR diversity in mice, and serum IL-7 in gastric cancer patients in combination with chemotherapy. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium.
[2] Espindola MS, et al. Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021 Feb 15;203(4):458-470. DOI:10.1164/rccm.201910-1977OC
AndecaliximabSupplier
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com